What are the side effects of Ilumya?
Medically reviewed by Drugs.com Last updated on Jun 19, 2018.
Official Answerby Drugs.com
The most common side effects of Ilumya are:
- upper respiratory infections (14% Ilumya vs. 12% placebo),
- injection site reactions (3% Ilumya vs. 2% placebo), and
- diarrhea (2% Ilumya vs. 1% placebo).
Upper respiratory infections include nasopharyngitis (common cold), upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. Injection site reactions may involve itching, pain, redness, swelling, bruising, hematoma (a solid blood clot under the skin), and bleeding.
Ilumya may also cause serious side effects such as allergic reactions with angioedema (swelling in the lower layers of the skin, often in the face, tongue, throat, arms or legs), urticaria (hives), and infections.
Before starting Ilumya, patients should be evaluated for tuberculosis.
In March, 2018 the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).
Related Medical Questions
- What are the new drugs for the treatment of plaque psoriasis?
- How does Ilumya work to treat psoriasis?
- How is Ilumya administered?
- What is the difference between Amjevita and Humira?
- What is the difference between Erelzi and Enbrel?
- What is the difference between Renflexis and Remicade?
- What is the Siliq REMS Program?
- Ilumya Information for Consumers
- Ilumya Information for Healthcare Professionals (includes dosage details)
- Side Effects of Ilumya (detailed)